Sellas Life Sciences Surges 156% in a Day on Cancer Vaccine Trial Win
New York-based clinical biopharmaceutical company Sellas Life Sciences Group Inc. (NASDAQ: SLS) delivered one of Wall Street's most explosive single-day rallies on Tuesday, November 17, 2026, surging 156 percent by the closing bell after soaring as much as 233 percent intraday on landmark late-stage clinical data for its experimental blood-cancer vaccine. Marking the stock's biggest one-day advance since 2020, the extraordinary buying frenzy erupted after Sellas reported positive topline findings from its pivotal Phase 3 REGAL clinical trial evaluating Galinpepimut-S (GPS)—an off-the-shelf immunotherapeutic cancer vaccine licensed from Memorial Sloan Kettering Cancer Center—in patients battling acute myeloid leukemia (AML). According to the trial results announced ahead of Tuesday's U.S. market open, Galinpepimut-S reduced the risk of death by 41 percent compared with the investigator's choice of best available standard therapy. Patients treated with the GPS vaccine achieved a median overall survival of 24 months, compared with under 15 months among patients receiving conventional care—a statistically significant and clinically meaningful survival extension in a fragile patient group that had achieved second complete remission (CR2) but was ineligible for stem-cell transplantation. Sellas Chief Executive Officer Angelos Stergiou hailed the outcome as a defining milestone, noting that extending survival without adding harsh systemic chemotherapy toxicity could prove transformative for heavily pretreated leukemia patients. Following the regular-session surge, however, shares pulled back roughly 12 percent in post-market trading after Sellas announced a $150 million public equity offering arranged through investment banks JPMorgan and TD Cowen to fund regulatory filings and commercialization. Meanwhile, data from analytics firm S3 Partners revealed that roughly 29 percent of Sellas's tradable float remained held in short positions following Tuesday's spike, underscoring sharp positioning battles between bullish biotech investors and short sellers. For healthcare professionals, biotech investors, and market observers across New Delhi, Mumbai, Bengaluru, Hyderabad, Ahmedabad, Chennai, Kolkata, Lucknow, and New York, Sellas's breakthrough marks a pivotal moment for therapeutic cancer vaccines.
Key Findings From Sellas's Phase 3 REGAL Trial and Market Reaction
Designed to train the body's CD4+ and CD8+ T-cells to recognize and eliminate residual leukemia cells expressing the WT1 (Wilms Tumor 1) protein, Galinpepimut-S cleared its primary overall survival endpoint in the 126-patient global study. The table below summarizes the clinical outcomes, regulatory roadmap, and Tuesday's dramatic Wall Street trading swings:
| Metric / Milestone | Verified Data & Details (November 17, 2026) | Clinical & Market Significance |
| Primary Endpoint: Overall Survival (OS) | Median OS of 24 months with Galinpepimut-S (GPS) vs. <15 months (14.7 months) on best available therapy. | Delivered a 41% reduction in the risk of death with a well-tolerated safety profile and no new safety signals. |
| Next Regulatory Step (U.S. FDA) | Sellas plans to meet with the U.S. FDA to pursue an accelerated approval pathway and file a Biologics License Application (BLA) in H1 2027. | Alliance Global Partners analyst James Molloy called results "incredibly clinically meaningful," projecting expedited FDA approval in 2027. |
| Regular-Session Stock Surge (NASDAQ: SLS) | Closed +156% higher on Nov 17, 2026 after peaking +233% intraday (biggest single-day jump since 2020). | Heavy institutional and retail volume poured into the stock as analysts re-rated Sellas's oncology pipeline. |
| After-Hours Offering & Short Interest | Announced a $150 million share sale via JPMorgan and TD Cowen (stock dipped ~12% post-market); 29% short interest per S3 Partners. | Capital raise strengthens cash reserves ahead of 2027 commercialization, while elevated short interest signals ongoing volatility. |
Why Galinpepimut-S Matters for the Broader Cancer Vaccine Landscape
Acute myeloid leukemia accounts for roughly one in three adult leukemia diagnoses, with the American Cancer Society estimating 22,720 new U.S. cases and 11,500 deaths in 2026. Patients who relapse or cannot undergo bone marrow transplants face bleak prognoses, making a well-tolerated maintenance vaccine that targets the WT1 antigen—expressed not only in AML but also across multiple solid tumors—a major therapeutic advance.
Industry analysts note that Sellas's Phase 3 triumph adds powerful clinical validation to the rapidly maturing cancer-vaccine field, building on momentum generated by Moderna and Merck & Co. in personalized mRNA melanoma vaccines. Because GPS is an off-the-shelf peptide vaccine rather than a bespoke patient-by-patient formulation, it also offers manufacturing scalability if approved by the FDA.
Why Short Sellers and Equity Dilution Keep Volatility High
Despite enthusiasm over Sellas's survival data and its companion CDK9 inhibitor candidate SLS009 (tambiciclib), Wall Street's post-market reaction illustrates classic biotech market dynamics. By immediately tapping JPMorgan and TD Cowen to raise $150 million in fresh equity capital, management moved swiftly to shore up its balance sheet—having reported zero commercial revenue and a $10.1 million quarterly loss earlier this month—at the cost of near-term share dilution that trimmed 12 percent off after-hours gains. With 29 percent of shares sold short according to S3 Partners, traders can expect sharp two-way swings as Sellas prepares for its upcoming FDA submission.